SPONSOR FEATURE

Driving change to defeat diabetes and other serious chronic diseases

he history of Novo In 1985, Novo Nordisk Nordisk dates back to the pioneered production of Ttime when insulin was recombinant human insulin in discovered. In 1922, the Danish yeast. In 1999, we introduced physiologist August Krogh rapid-acting and, in 2004, long- met with to-be fellow Nobel acting insulin analogues produced Prize laureates Frederick Grant by genetic engineering, allowing Banting and John James Richard users to mimic physiological Macleod in Toronto, Canada, insulin secretion to avoid and secured the rights to supply hypoglycaemia around mealtimes insulin in Scandinavia. as well as overnight. Today, Novo Nordisk has Novo Nordisk as a current become a leading healthcare market leader offers multiple company and we strive to use widely used insulin analogues, our capabilities to tackle unmet including long-acting insulin medical needs in diabetes, degludec, rapid-acting insulin obesity and other serious chronic aspart, and premix insulin diseases (Fig. 1). preparations including the combination of insulin degludec A SUSTAINABLE BUSINESS and aspart. We engage with partners globally To improve the convenience of to address the root causes of our medicines, we introduced the Figure 1. Novo Nordisk at a glance. Data from Novo Nordisk Annual Report 2020; S&P disease, for example with the world’s first pen-shaped devices for Global Market Intelligence on behalf of MedWatch.dk. United Nations International subcutaneous injection in 1985. Children’s Emergency Fund to introduce a GLP-1 analogue A BRIGHT FUTURE (UNICEF) to prevent childhood GLP-1 ANALOGUES (a large peptide) delivered in a Our commitment to finding obesity, and we established and Collaborating with academic tablet for systemic exposure. preventive or protective continuously invest in the World researchers, Novo Nordisk By developing next-generation interventions remains strong. Diabetes Foundation and the Novo pioneered translating GLP-1 analogues and other We hope to leverage our 20- Nordisk Haemophilia Foundation. glucagon-like peptide 1 (GLP- medicines in our pipeline, we year experience researching We commit to providing 1) from incretin hormone to envision a future where diabetes stem-cell replacement therapies access to affordable medicines pharmacologically useful GLP-1 and other serious chronic to introduce regenerative for vulnerable patients and we analogues for the treatment diseases such as obesity and interventions. support capacity building within of diabetes and obesity. Our cardiovascular disease can be Novo Nordisk remains healthcare systems for the future. expertise in protein engineering, treated with safe medicines. Here, focused on raising the originating in insulin research, GLP-1 compounds are particularly innovation bar and we continue CHANGING DIABETES has enabled once-daily and promising: they effectively to collaborate with academic The discovery of insulin was once-weekly GLP-1 analogues reduce blood glucose, weight and and clinical scientists, and not only a miracle for people that effectively control blood cardiovascular risk, and they are with biotech companies and living with diabetes, but a glucose in type 2 diabetes with being explored in diseases with pharmaceutical peers to develop foundation for modern medicine low risk of hypoglycaemia. urgent unmet needs, including innovative therapies for serious and biotechnology. GLP-1 analogues can also offer non-alcoholic steatohepatitis, chronic diseases. To mimic physiological significant weight loss for people chronic kidney disease and insulin release, both long- with diabetes or obesity. Alzheimer’s disease. acting and short-acting insulin Today, Novo Nordisk is preparations are needed. After the world’s leading supplier RARE DISORDERS AUTHORS Bernt Johan von Scholten, decades of optimizations to of injectable GLP-1-based For decades, we have produced Frederik Flindt Kreiner, develop longer-acting insulin therapies for type 2 diabetes advanced medicines to help Stephen Charles Langford Gough and preparations to reduce the with once-daily liraglutide and individuals with haemophilia. Peter Kurtzhals. number of daily injections, in once-weekly semaglutide, as In addition, we lead in growth ADDRESS 1946 we introduced Neutral well as for weight management. hormone deficiency, which affects Global Chief Medical Office, Novo Protamine Hagedorn insulin for With oral semaglutide for type at least 1 in every 3,500 newborn Nordisk A/S, Vandtaarnsvej 110, DK- twice-daily injection. 2 diabetes, we were the first children as well as many adults. 2860, Søborg, Denmark

Sponsor retains sole responsibility for content